National Cancer Institute Completes 1,000-Patient Natural History and Specimen Study on Central Nervous System Tumors
Study Design and Completion Significance
The National Cancer Institute (NCI) has transitioned its NCT02851706 study, initiated in 2016, to a completed status. This is not a Phase 1·2·3 clinical trial involving investigational drugs, but rather an observational natural history study of adult central nervous system (CNS) tumor patients over the long term. Analysis of the first 1,000 patients, enrolled from September 2016 to July 2023, was published in 2026. At enrollment, patient-reported outcomes (PRO) were collected at 97%, and clinical data from healthcare providers were obtained at 99%. The study's key contribution lies in structuring the natural course and treatment outcomes in rare and molecularly heterogeneous CNS tumors.
Data and Specimen Utility
Researchers linked clinical records, neuroimaging, pathology, blood, cerebrospinal fluid, previously surgically obtained tissue, and genomic DNA. Individual data based on medical records are accessible to approved researchers via the Biomedical Translational Research Information System (BTRIS), while large-scale genomic data are shared through the genotype-phenotype database (dbGaP). Combining longitudinal clinical outcomes, symptoms, and molecular information from the same patient can support hypothesis design for external control groups and biomarkers in small rare tumor trials. However, it must be distinguished from randomized comparative studies as it does not serve as a basis for drug approval.
Treatment Competition and Regulatory Context
This study does not involve investigational drugs, brand names, or single molecular targets, nor does it assign clinical trial phases. Standard treatment for glioblastoma includes surgery followed by radiation and temozolomide (a DNA alkylating agent), with Novocure’s Optune (tumor-treating field) added. The FDA approved Optune in combination with temozolomide on October 5, 2015. For recurrent glioblastoma, Roche’s (ROG.SW) bevacizumab (VEGF-A-targeting antibody) is an approved treatment. In low-grade gliomas, Servier’s vorasidenib (IDH1·IDH2 inhibitor) received FDA approval on August 6, 2024, changing the standard for molecularly selected therapies.
Patient, Market, and Industry Value
According to the NCI, in the U.S., brain and other nervous system cancers are expected to affect 24,820 new patients and cause 18,330 deaths in 2025, with a 5-year relative survival rate of 33.0%. The U.S. glioblastoma treatment market was estimated at $1.4442 billion in 2025, with a global market size of $4.04 billion. The NCI dataset is not an asset generating direct revenue but serves as a public research infrastructure necessary for patient selection of drug candidates, natural history comparisons, and discovery of rare molecular subtypes. Particularly in rare CNS tumors where recruitment for randomized controlled trials is difficult, it is evaluated as a foundation to reduce clinical development time and the burden of control group design.
From an investment perspective, NCT02851706 does not generate revenue or exclusivity rights itself, but the 1,000-patient longitudinal clinical and genomic dataset lowers the cost of patient segmentation and external control group construction in the $1.4442 billion U.S. glioblastoma market in 2025. For researchers, the high initial collection rate of 97% PRO and 99% clinical data, along with the BTRIS and dbGaP sharing system, provides a foundation to validate hypotheses on rare molecular subtypes. For the industry, it offers resources to refine registration criteria and biomarker design for Phase 1·2 candidates, but it cannot be directly used as evidence for efficacy and safety comparisons, as it is an observational study. Mid- to long-term competitive dynamics will form between glioblastoma treatments centered on temozolomide, Optune, and bevacizumab, and the FDA-approved vorasidenib’s IDH1·IDH2-targeted precision medicine.
Source: ClinicalTrials.gov (api_ct)